Skip to main content

Table 3 Results of the base case model after 3 years

From: Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis

  % progress to ESRD (95%CI) Life years lived (95%CI) Costs (€) (95%CI)
Moxonidine 7.5% (3.5–12.7) 2.950 (2.937–2.959) €9,858 (5,501–16,174)
Nitrendipine 38.9% (31.8–45.8) 2.907 (2.882–2.927) €37,472 (27,957–49,478)